Table 2.
Clinical characteristics of patients with hepatitis B-caused cirrhosis before and after propensity score matching.
| Variable | Before propensity matching | After propensity matching | ||||
|---|---|---|---|---|---|---|
| TCM user (n = 270) | Non-TCM users (n = 572) | P value | TCM user (n = 259) | Non-TCM users (n = 259) | P value | |
| Age, years | 50.0 (42.0, 59.0) | 50.0 (42.0, 58.0) | 0.525 | 50.0 (42.0, 59.0) | 49.0 (42.0, 58.0) | 0.234 |
| Male sex, n (%) | 191 (70.7%) | 393 (68.7%) | 0.550 | 184 (71.0%) | 168 (64.8%) | 0.132 |
| Family history of HCC, n (%) | 19 (7.0%) | 33 (5.8%) | 0.476 | 18 (6.9%) | 16 (6.2%) | 0.723 |
| Smoking, n (%) | 61 (22.6%) | 128 (22.4%) | 0.944 | 58 (22.4%) | 58 (22.4%) | 1.000 |
| Alcohol consumption, n (%) | 41 (15.2%) | 85 (14.9%) | 0.984 | 39 (15.1%) | 39 (15.1%) | 1.000 |
| Diabetes, n (%) | 57 (21.1%) | 85 (14.9%) | 0.024 | 53 (20.5%) | 49 (18.9%) | 0.659 |
| Hypertension, n (%) | 55 (20.4%) | 80 (13.9%) | 0.018 | 50 (19.3%) | 44 (16.9%) | 0.494 |
| Ascites, n (%) | 46 (17.0%) | 77 (13.4%) | 0.170 | 45 (17.3%) | 41 (15.8%) | 0.637 |
| Hepatic encephalopathy, n (%) | 14 (5.2%) | 18 (3.1%) | 0.149 | 14 (5.4%) | 10 (3.9%) | 0.403 |
| Gastroesophageal varices, n (%) | 69 (25.5%) | 137 (23.9%) | 0.613 | 65 (25.1%) | 81 (31.3%) | 0.118 |
| HBeAg positivity, n (%) | 143 (52.9%) | 296 (51.7%) | 0.818 | 139 (53.6%) | 126 (48.6%) | 0.206 |
| CTP score, n (%) | 8.0 (6.0, 10.0) | 8.0 (6.0, 10.0) | 0.837 | 8.0 (6.0, 10.0) | 8.0 (6.0, 10.0) | 0.130 |
| MELD score, n (%) | 10.3 (8.2, 13.2) | 10.3 (8.3, 12.9) | 0.822 | 10.3 (8.3, 13.2) | 10.7 (8.4, 13.6) | 0.573 |
| Alanine aminotransferase, U/L | 37.9 (24.1, 80.2) | 36.4 (24.0, 76.5) | 0.744 | 37.7 (24.1, 78.3) | 37.0 (27.2, 114.5) | 0.139 |
| Aspartate aminotransferase, U/L | 43.3 (30.8, 76.7) | 42.9 (29.1, 85.3) | 0.622 | 43.3 (31.5, 76.5) | 46.5 (31.9, 111.0) | 0.132 |
| Total bilirubin, μmol/L | 27.1 (18.6, 44.8) | 23.7 (14.6, 39.7) | 0.004 | 27.2 (18.9, 44.6) | 29.5 (16.7, 48.0) | 0.838 |
| Albumin, g/L | 32.2 (27.9, 37.1) | 32.2 (27.7, 37.5) | 0.798 | 32.4 (27.9, 37.0) | 32.2 (27.4, 36.4) | 0.329 |
| Gamma-glutamyl transferase, U/L | 50.3 (24.7, 90.9) | 35.7 (20.3, 83.9) | 0.010 | 50.0 (24.9, 90.8) | 38.5 (20.8, 85.1) | 0.102 |
| White blood cell count, ×109/L | 4.2 (3.2, 5.4) | 3.6 (2.6, 5.1) | 0.001 | 4.0 (3.1, 5.3) | 3.8 (2.7, 5.7) | 0.278 |
| Platelets, ×109/L | 71.0 (50.4, 101.0) | 68.0 (47.2, 99.0) | 0.715 | 71.0 (50.0, 101.0) | 69.8 (51.8, 101.0) | 0.731 |
| Creatinine, μmol/L | 64.0 (53.0, 73.4) | 65.9 (56.3, 75.0) | 0.027 | 64.4 (53.5, 73.9) | 63.0 (55.0, 72.0) | 0.737 |
| Blood urea nitrogen, mmol/L | 5.2 (4.2, 6.8) | 5.8 (4.1, 6.9) | 0.644 | 5.2 (4.2, 6.9) | 5.2 (3.8, 6.8) | 0.367 |
| International normalized ratio | 1.2 (1.1, 1.3) | 1.2 (1.1, 1.4) | 0.673 | 1.2 (1.1, 1.3) | 1.2 (1.1, 1.3) | 0.726 |
| Prothrombin activity,% | 61.0 (50.0, 76.0) | 60.0 (48.0, 68.0) | 0.021 | 61.0 (50.0, 76.0) | 61.0 (50.0, 73.0) | 0.811 |
| Alpha-fetoprotein, ng/ml | 10.0 (4.0, 64.4) | 6.4 (3.2, 33.0) | 0.006 | 10.0 (4.0, 63.5) | 9.0 (4.2, 47.9) | 0.926 |
| HBV DNA, log10IU/ml | 4.2 (2.7, 5.7) | 3.8 (2.7, 5.6) | 0.118 | 4.1 (2.7, 5.7) | 4.0 (2.7, 5.7) | 0.881 |
Data are presented as n (%) or median (interquartile range). CTP: Child-Turcotte-Pugh; MELD: Model for End-Stage Liver Disease.